Biotech 2050 Podcast cover image

New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio

Biotech 2050 Podcast

CHAPTER

Cambrian's Approach to Drug Development

Cambrian currently has 15 drugs in development, including eight candidates. One program is moving into a phase one B later this year that we haven't announced yet. We tend to take a slightly slower approach to the maximum possible speed of taking a tool compound and rushing that into humans. And so we get on board with these kind of in vivo validation of a mechanism.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner